WVE Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
13.2M
+479.1%
2.3M
-94.1%
38.2M
+121.8%
17.2M
+126.7%
7.6M
Cost of Revenue
0
0
0
0
0
Gross Profit
13.2M
+479.1%
2.3M
-94.1%
38.2M
+121.8%
17.2M
+126.7%
7.6M
Operating Expenses
79.2M
+4.1%
76.1M
+9.4%
69.5M
-5.7%
73.7M
+15.2%
64.0M
R&D
53.8M
+5.0%
51.3M
+8.1%
47.4M
-10.2%
52.8M
+15.1%
45.9M
SG&A
25.4M
+2.3%
24.8M
+12.1%
22.1M
+5.8%
20.9M
+15.5%
18.1M
Operating Income
-66047000
+10.5%
-73802000
-135.8%
-31298000
+44.6%
-56467000
-0.2%
-56353000
EBITDA
-65167000
+10.7%
-72944000
-139.5%
-30457000
+45.2%
-55623000
-0.2%
-55497000
Net Income
-61912000
+10.7%
-69355000
-165.9%
-26087000
+50.9%
-53179000
+1.2%
-53852000
EPS (Basic)
$-0.30
+11.8%
$-0.34
-161.5%
$-0.13
+55.2%
$-0.29
+9.4%
$-0.32
EPS (Diluted)
$-0.30
+11.8%
$-0.34
-161.5%
$-0.13
+55.2%
$-0.29
+9.4%
$-0.32
Shares (Diluted)
204.2M
+0.1%
204.0M
+1.9%
200.2M
+11.0%
180.3M
+7.5%
167.7M
Wave Life Sciences (WVE) — Financials